Catalysts for $AMGN
166 tracked
Aug 20, 2024
approval
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Jul 22, 2024
approval
ENBREL (ETANERCEPT) — FDA approval
AMGEN INC
→
Jul 22, 2024
approval
ENBREL (ETANERCEPT) — FDA approval
AMGEN INC
→
Jul 22, 2024
approval
ENBREL (ETANERCEPT) — FDA approval
AMGEN INC
→
Jun 14, 2024
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
May 28, 2024
approval
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
May 16, 2024
approval
IMDELLTRA (TARLATAMAB-DLLE) — FDA approval
tarlatamab
→
Apr 25, 2024
approval
OTEZLA (APREMILAST) — FDA approval
apremilast
→
Feb 8, 2024
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Oct 31, 2023
approval
WEZLANA (USTEKINUMAB-AUUB) — FDA approval
WEZLANA
→
Oct 31, 2023
approval
WEZLANA (USTEKINUMAB-AUUB) — FDA approval
WEZLANA
→
Oct 18, 2023
approval
ENBREL (ETANERCEPT) — FDA approval
AMGEN INC
→
Aug 14, 2023
approval
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Jul 20, 2023
approval
OTEZLA (APREMILAST) — FDA approval
apremilast
→
Jul 12, 2023
approval
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Jun 20, 2023
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 20, 2023
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 9, 2023
approval
ENBREL (ETANERCEPT) — FDA approval
AMGEN INC
→
Apr 6, 2023
approval
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Mar 22, 2023
approval
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Dec 5, 2022
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Aug 16, 2022
approval
ENBREL (ETANERCEPT) — FDA approval
AMGEN INC
→
Jul 28, 2022
approval
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Jun 17, 2022
approval
ENBREL (ETANERCEPT) — FDA approval
AMGEN INC
→
Feb 18, 2022
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Dec 20, 2021
approval
OTEZLA (APREMILAST) — FDA approval
apremilast
→
Mar 11, 2021
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Feb 26, 2021
approval
ENBREL (ETANERCEPT) — FDA approval
AMGEN INC
→